Skip to main content

Advertisement

Table 1 Baseline characteristics of the IMPROVED study population

From: Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)

  Total n = 610 Early remission n = 387 Arm 1 n = 83 Arm 2 n = 78 OOP n = 50
DAS, mean ± SD 3.2 ± 0.9 3.0 ± 0.8 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
HAQ, mean ± SD 1.2 ± 0.7 1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.6 1.3 ± 0.7
Age in years, mean ± SD 52 ± 14 52 ± 14 49 ± 14 51 ± 14 54 ± 14
Female, n (%) 414 (68) 240 (62) 64 (77) 58 (74) 42 (84)
Symptom duration (weeks), median (IQR) 18 (9–32) 17 (9–30) 22 (9–41) 21 (8–31) 18 (9–42)
RF-positive, n (%) 339 (56) 224 (58) 41 (49) 43 (55) 23 (46)
ACPA-positive, n (%) 333 (55) 225 (58) 40 (48) 37 (47) 25 (50)
RA (2010 criteria), n (%) 479 (79) 298 (77) 66 (80) 66 (85) 40 (80)
Swollen joint count, median (IQR) 5 (3–10) 5 (2–9) 6 (3–10) 8 (4–12) 7 (3–13)
Tender joint count, median (IQR) 6 (4–9) 5 (3–8) 8 (6–13) 9 (6–13) 8 (6–14)
ESR mm/h, median (IQR) 25 (11–39) 23 (8–38) 28 (13–41) 22 (11–41) 29 (16–42)
VAS global health (mm), mean ± SD 46 ± 23 43 ± 24 53 ± 20 54 ± 22 49 ± 23
Total SHS, median (IQR) 0 (0–1.0) 0 (0–0.5) 0 (0–0) 0 (0–0) 0 (0–0)
Erosive, n (%) 89 (15) 63 (16) 10 (12) 13 (17) 3 (6)
  1. After 4 months 12 patients were lost to follow up and 598 patients were categorized as described in Table 1. Arm 1: randomized at 4 months to methotrexate, sulphasalazine, hydroxychloroquine and low-dose prednisone. Arm 2: randomized at 4 months to methotrexate and adalimumab. OOP outside of protocol, SD standard deviation, IQR interquartile range, n number, DAS disease activity score, HAQ health assessment questionnaire, RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, RA (2010) rheumatoid arthritis according to the 2010 classification criteria, ESR erythrocyte sedimentation rate, VAS visual analogue scale, SHS Sharp-van de Heijde score, Erosive at least 1 erosion